Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
S Peters
,
U Dafni
,
M Boyer
,
D De Ruysscher
,
C Faivre-Finn
,
E Felip
,
P Garrido
,
N Girard
,
M Guckenberger
,
J Haanen
,
C Le Pechoux
,
F Mornex
,
M Ozsahin
,
L Paz-Ares
,
D Planchard
,
D Raben
,
S Ramalingam
,
M Reck
,
E Smit
,
R Stahel
,
A Stenzinger
,
C Swanton
,
S Vallone
,
M C Garassino
More about this publication
Annals of oncology : official journal of the European Society for Medical Oncology
Volume
30
Issue nr.
2
Pages
161-165
Publication date
01-02-2019
Full text links
Publisher website (DOI)
10.1093/annonc/mdy553
Europe PubMed Central
30624547
Pubmed
30624547